Raynauds Disease Treatment Global Market Report 2026

Raynaud's disease treatment involves medical and lifestyle approaches designed to lessen the frequency and intensity of blood vessel spasms in the fingers and toes that are triggered by cold exposure or stress. It includes the use of medications, such as calcium channel blockers, to improve blood circulation, along with preventive measures like staying warm and managing stress.

The main types of treatments for Raynaud's disease include medication, thermal therapies, surgical procedures, and alternative therapies. Medications consist of drugs such as calcium channel blockers and vasodilators that enhance blood flow and reduce the severity of Raynaud's symptoms. These treatments involve various drug classes, including calcium channel blockers, vasodilators, and antiplatelet agents, and are administered through oral, topical, injectable, and intravenous routes. They are used by end users such as hospitals, specialty clinics, homecare settings, and pharmacies.

Tariffs have affected the raynauds disease treatment market by increasing costs for imported medications, thermal therapy devices, and surgical instruments. Segments such as calcium channel blockers, biofeedback-controlled thermal devices, and surgical equipment are most impacted, particularly in regions like North America and Europe that rely on imports from Asia. This has led to higher treatment costs and supply chain challenges. On the positive side, tariffs have encouraged local manufacturing of devices and medications, boosting domestic production capabilities and innovation in alternative therapies.

The raynauds disease treatment market research report is one of a series of new reports from The Business Research Company that provides raynauds disease treatment market statistics, including raynauds disease treatment industry global market size, regional shares, competitors with a raynauds disease treatment market share, detailed raynauds disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the raynauds disease treatment industry. This raynauds disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The raynauds disease treatment market size has grown strongly in recent years. It will grow from $1.49 billion in 2025 to $1.6 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to limited awareness of raynauds disease, reliance on conventional medication, growing hospital and specialty clinic infrastructure, lack of homecare options, seasonal demand fluctuations.

The raynauds disease treatment market size is expected to see strong growth in the next few years. It will grow to $2.13 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to development of novel pharmacological therapies, adoption of wearable thermal therapy devices, increasing awareness of preventive care and lifestyle management, growth in homecare and telehealth services, integration of digital health monitoring and biofeedback technologies. Major trends in the forecast period include rising adoption of calcium channel blockers and vasodilators, increased use of thermal therapy devices and biofeedback systems, growing preference for minimally invasive surgical procedures, expansion of homecare and specialty clinic settings, emphasis on lifestyle and stress management programs.

The rising prevalence of autoimmune diseases is anticipated to drive the growth of the Raynaud's disease treatment market in the coming years. Autoimmune diseases are conditions in which the immune system mistakenly attacks the body's own healthy tissues, leading to inflammation and tissue damage. The increasing occurrence of autoimmune diseases is attributed to greater urbanization and highly sanitized living environments, which limit immune system conditioning, along with modern lifestyle factors such as unhealthy diets, chronic stress, and exposure to environmental pollutants. Raynaud's disease treatment supports autoimmune conditions by improving symptom management, minimizing tissue damage, and preventing complications associated with reduced blood flow. For instance, in February 2024, according to Clinical Trials Arena, a UK-based platform covering clinical trials and pharmaceutical developments, projections suggest that global cases of rheumatoid arthritis (RA) are expected to rise significantly, with prevalence forecast to increase by 80.2% and impact nearly 1% of the world's population by 2050. Therefore, the increasing prevalence of autoimmune diseases is fueling the growth of the Raynaud's disease treatment market.

The growth in healthcare expenditure is also expected to propel the expansion of the Raynaud's disease treatment market going forward. Healthcare expenditure refers to the total spending on medical services, treatments, and health-related resources over a specific period. Healthcare spending is increasing substantially due to the expanding aging population, which drives higher demand for medical care, long-term treatment, and therapies for age-related conditions, thereby placing greater pressure on healthcare systems. Increased healthcare expenditure enhances Raynaud's disease treatment by improving access to medications, advanced diagnostic tools, specialized care services, research into new therapies, and awareness initiatives that support effective symptom management. For instance, in April 2025, according to the American Medical Association, a US-based professional association, health spending in the United States increased by 7.5% in 2023, reaching $4.9 trillion, or $14,570 per person, compared with a growth rate of 4.6% in 2022. Therefore, rising healthcare expenditure is driving the growth of the Raynaud's disease treatment market.

Major companies operating in the Raynaud's disease treatment market are concentrating on developing innovative therapies, such as oral calcium channel blockers, to enhance blood flow by relaxing and dilating blood vessels, thereby lowering the frequency and severity of vasospastic episodes. An oral calcium channel blocker is a medication administered by mouth that relaxes and widens blood vessels by inhibiting calcium entry into the muscle cells of the heart and vascular walls. For example, in June 2023, Aisa Pharma Inc., a US-based clinical-stage biopharmaceutical company, initiated the second phase of its Phase 2b RECONNOITER trial to assess Profervia (cilnidipine), an oral calcium channel blocker, for the treatment of Raynaud's phenomenon in individuals with systemic sclerosis (SSc). This followed encouraging results from the earlier phase, in which Profervia demonstrated a greater reduction in Raynaud's attack frequency and SSc disease severity compared with other calcium channel blockers, while maintaining a favorable safety and tolerability profile. The ongoing trial, utilizing a 20 mg dose, seeks to address the significant unmet need for effective treatments for Raynaud's associated with systemic sclerosis, a condition for which no approved therapies currently exist.

Major companies operating in the raynauds disease treatment market are Pfizer Inc., Johnson & Johnson, Bayer AG, Novartis AG, Sanofi SA, AstraZeneca PLC, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., CSL Vifor, Orion Corporation, Apricus Biosciences Inc., Vicore Pharma Holding AB, MediQuest Therapeutics Inc., Gesynta Pharma AB, Aisa Pharma Inc., Abbott Laboratories, Boehringer Ingelheim International GmbH, Viatris Inc., Lupin Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Aurobindo Pharma Ltd., Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC, Alkem Laboratories Ltd.

North America was the largest region in the raynauds disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the raynauds disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the raynauds disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The raynauds disease treatment market consists of revenue earned by entities by providing services such as pharmacological management, thermal therapy services, surgical consultation, and behavioral therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The raynauds disease treatment market also includes sales of vasodilators, prostaglandins, hand warmers, thermal gloves, heated socks, and paraffin wax baths. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Raynauds Disease Treatment Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses raynauds disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for raynauds disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The raynauds disease treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Treatment Type: Medication; Thermal Therapies; Surgical Procedures; Alteative Therapies
• 2) By Drug Class: Calcium Channel Blockers; Vasodilators; Antiplatelet Agents
• 3) By Route of Administration: Oral; Topical; Injectable; Intravenous
• 4) By End-User: Hospitals; Specialty Clinics; Homecare Settings; Pharmacies
• Subsegments:
• 1) By Medication: Calcium Channel Blockers; Alpha Blockers; Vasodilators; Topical Nitrates; Selective Serotonin Reuptake Inhibitors (SSRIs); Phosphodiesterase Inhibitors; Angiotensin Receptor Blockers (ARBs)
• 2) By Thermal Therapies: Hand Warmers; Thermal Gloves; Heated Pads; Biofeedback-Controlled Thermal Devices
• 3) By Surgical Procedures: Sympathectomy; Nerve Decompression Surgery; Vascular Surgery
• 4) By Alternative Therapies: Acupuncture; Biofeedback Therapy; Herbal Remedies; Nutritional Supplements; Stress Management Techniques
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Bayer AG; Novartis AG; Sanofi SA; AstraZeneca PLC; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Merck & Co. Inc.; Teva Pharmaceutical Industries Ltd.; CSL Vifor; Orion Corporation; Apricus Biosciences Inc.; Vicore Pharma Holding AB; MediQuest Therapeutics Inc.; Gesynta Pharma AB; Aisa Pharma Inc.; Abbott Laboratories; Boehringer Ingelheim International GmbH; Viatris Inc.; Lupin Limited; Sun Pharmaceutical Industries Ltd.; Dr. Reddy's Laboratories Ltd.; Cipla Limited; Torrent Pharmaceuticals Ltd.; Zydus Lifesciences Ltd.; Aurobindo Pharma Ltd.; Glenmark Pharmaceuticals Ltd.; Intas Pharmaceuticals Ltd.; Hikma Pharmaceuticals PLC; Alkem Laboratories Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.